Research
Hormonal
Tirzepatide (5-15 mg) produces significantly greater weight loss, waist circumference reduction, and HbA1c improvement compared to placebo, insulin, and GLP-1 receptor agonists in adults with type 2 diabetes or obesity.
Tirzepatide is a highly effective treatment for weight loss and blood sugar control, outperforming existing GLP-1 drugs and insulin. It requires weekly injections and careful dose titration to manage gastrointestinal side effects like nausea.
StrongSupportsHIGH confidence
Tirzepatide significantly increased the proportion of participants achieving weight loss targets, and reduced body weight, waist circumference, HbA1c, and blood pressure versus placebo and insulin. Compared with GLP-1 RAs, tirzepatide provided comparable or better outcomes in weight loss, waist circumference, and glycemic control.
Why this rating
Meta-analysis of 14 RCTs with 14,713 patients.
Source
The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ligang Liu et al. · Pharmaceuticals · 2025
Meta-analysis · 14 studiesCited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →